Copenhagen, 2013-02-05 08:48 CET (GLOBE NEWSWIRE) --
ALK advanced its research and development pipeline and made progress with its sales of several new products in 2012. Progress in the partnerships in North America and Japan also contributed to ALK's important steps towards fulfilling the objective of globalising allergy immunotherapy. Financial performance was affected by challenged markets in Europe with low or negative market growth.
Total revenue was DKK 2,345 million (2,348). Operating profit before depreciation and amortisation (EBITDA) before special items reached DKK 306 million (406).
The Board of Directors proposes a dividend of DKK 5 per share to the annual general meeting.
See page 3 in the attached annual report 2012 for highlights of the year.
Audio cast
Today, ALK hosts a meeting for analysts and institutional investors at 1.00 p.m. (CET) at which Jens Bager, President and CEO, and Flemming Pedersen, CFO, will review the financial results, the outlook and answer questions. The meeting will be audio cast on www.alk-abello.com/investor.
Participants in the audio cast are kindly requested to call in before 12.55 p.m. (CET). Danish participants should call in on tel. +45 70 26 50 40 and international participants should call in on tel. +44 20 8817 9301. The audio cast is available live on our website, where the related presentation will be available shortly before the meeting begins.
ALK-Abelló A/S
Jens Bager
President and CEO
For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143